{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"groups":[{"description":"Patients receive G-CSF SC QD on days 1-4.\n\nfilgrastim: Given SC","id":"OG000","title":"Arm I: Control"},{"description":"Patients receive G-CSF SC QD on days 1-4 and plerixafor SC QD on days 4-8.\n\nplerixafor: Given SC\n\nfilgrastim: Given SC","id":"OG001","title":"Arm II: Experimental"}],"populationDescription":"Due to low enrollment (10% of anticipated participants), no analysis is being done on data collected in this study","reportingStatus":"POSTED","timeFrame":"In =< 5 days of leukaphereses","title":"Percentage of Patients Achieving Target Goal CD34+ Cells Dose","type":"SECONDARY"}